ArticleJournal of clinical microbiology2011
Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 151 citations in OpenAlex.
- Influence of environmental and nutritional conditions on Nakaseomyces glabratus biofilm development in vitro.Archives of microbiology · 2026Article
- Protective effects of cell-free supernatants from a kefir-derived microbial consortium against multidrug-resistant Candida glabrata associated with vulvovaginal candidiasis.Medical mycology · 2026Article
- Article
- Fungal biofilms in human health and disease.Nature reviews. Microbiology · 2025Review
- Virulence profile of pathogenic yeasts from snakes: Alternative ways for antifungal strategies.PloS one · 2025Article
- SUMO-targeted Ubiquitin Ligases as crucial mediators of protein homeostasis in Candida glabrata.PLoS pathogens · 2024Article
- Surfactants' Interplay with Biofilm Development inPharmaceutics · 2024Article
- Anti-Biofilm Activity of Assamsaponin A, Theasaponin E1, and Theasaponin E2 againstInternational journal of molecular sciences · 2024Article
- Article
- Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole.Microbiology spectrum · 2024Article
- Therapeutic effect of iturin A onAntimicrobial agents and chemotherapy · 2024Article
- Article
- Visible-Light-Activated Molecular Machines Kill Fungi by Necrosis Following Mitochondrial Dysfunction and Calcium Overload.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- ROS mediated anticandidal efficacy of 3-Bromopyruvate prevents vulvovaginal candidiasis in mice model.PloS one · 2023Article
- Exploring the biomedical potential of a novel modified glass ionomer cement against the pandrug-resistant oral pathogenJournal of oral microbiology · 2023Article
- A common vesicle proteome drives fungal biofilm development.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Membrane Integrity Contributes to Resistance of Cryptococcus neoformans to the Cell Wall Inhibitor Caspofungin.mSphere · 2022Article
- An intestinalVeterinary world · 2022Article
- Anti-Adhesion and Antibiofilm Activity ofPlants (Basel, Switzerland) · 2022Article
- Optotracing for live selective fluorescence-based detection ofFrontiers in cellular and infection microbiology · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Candida spp. infect medical devices, such as venous and urinary catheters, by adhering to the surface and forming a community of drug-resistant cells surrounded by a matrix. The ability to measure drug activity during this biofilm mode of growth is of interest for the investigation of resistance mechanisms and novel antifungal therapies. The tetrazolium salt (XTT) reduction assay is the test most commonly used to estimate viable biofilm growth and to examine the impact of biofilm therapies. The primary goal of the current experiments was to identify assay variables that affect the XTT assay result in order to improve assay reproducibility, sensitivity, and throughput for the study of antifungal activity. The species used in the current studies included Candida albicans, C. parapsilosis, and C. glabrata. The assay variables that were studied included the impact of culture conditions, the duration of biofilm growth, the timing and frequency of drug administration, the XTT source and concentration, and the duration of XTT incubation. The conditions that impacted the assay readout and altered assay sensitivity included the duration of biofilm growth, the frequency of drug dosing, and the duration of XTT incubation. Several factors were found to reduce time and assay expense, including the elimination of washing steps, the shortening of incubation times, and the use of lower XTT concentrations. A description of assay pitfalls and troubleshooting is included. Recognition of these technical variables should allow investigators to better design reproducible biofilm therapeutic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.